Michael R. Galambos
Expertise in
72
conditions

Dr. Michael R. Galambos

Gastroenterology | Hepatology
95 Collier Rd NW, Suite 4085, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
72
conditions
95 Collier Rd NW, Suite 4085, 
Atlanta, GA 

Overview

Michael Galambos is a Gastroenterologist and a Hepatologist practicing medicine in Atlanta, Georgia.

Dr. Galambos is highly rated in 72 conditions, according to our data. His clinical expertise encompasses Primary Biliary Cholangitis, Turcot Syndrome, Gardner Syndrome, Endoscopy, and Colonoscopy.

Dr. Galambos is board certified in American Board Of Internal Medicine - Gastroenterology and American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 12 clinical trials. Dr. Galambos is currently accepting new patients.

Specialties

Gastroenterology
Hepatology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine - Gastroenterology
American Board Of Internal Medicine

Fellowships

Emory University School of Medicine, 1989

Hospital Affiliations

Piedmont Mountainside Hospital Inc
Northside Hospital Forsyth
Northside Hospital Cherokee
Piedmont Hospital, Inc
Union General Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Digestive Healthcare of Georgia - Atlanta Suite 4085
95 Collier Rd NW, Suite 4085, Atlanta, GA 30309

Additional Areas of Focus

Dr. Galambos has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2026
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Journal: Alimentary pharmacology & therapeutics
Published: July 28, 2023
Similar Doctors
Expertise in
52
conditions
Dr. Bryan L. Woods
Gastroenterology | Hepatology
Expertise in
52
conditions
Dr. Bryan L. Woods
Gastroenterology | Hepatology
Referral may be required
Before you request

Digestive Healthcare Of Georgia - Fayette

1265 West Highway 54 Suite 402, 
Fayetteville, GA 
 (22.6 miles away)
678-817-6550
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hospital Affiliation Piedmont Fayette Hospital Piedmont Newnan Hospital Board Certification: Gastroenterology Education and Training Medical School: University of Tennessee Internship: Emory University Residency: Emory University Fellowship: University of South Carolina. Dr. Woods is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Lower Esophageal Ring, Benign Esophageal Stricture, Familial Adenomatous Polyposis, Endoscopy, and Gastrectomy. Dr. Woods is board certified in American Board Of Internal Medicine. Dr. Woods is currently accepting new patients.

Expertise in
14
conditions
Dr. Parit Mekaroonkamol
Gastroenterology
Expertise in
14
conditions
Dr. Parit Mekaroonkamol
Gastroenterology
Referral may be required

Emory University School Of Medicine Department Of Ophthalmology

1365 Clifton Rd NE, 
Atlanta, GA 
 (4.4 miles away)
404-778-3184
Languages Spoken:
English

Parit Mekaroonkamol is a Gastroenterologist practicing medicine in Atlanta, Georgia. Dr. Mekaroonkamol is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Pancreas Divisum, Gastroparesis, Cholecystitis, Gastrectomy, and Endoscopy.

Expertise in
28
conditions
Dr. Steven A. Keilin
Gastroenterology
Expertise in
28
conditions
Dr. Steven A. Keilin
Gastroenterology
Referral may be required
Before you request

Emory Clinic At 1365 Clifton Road

1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 
 (4.1 miles away)
404-778-3184
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Keilin is a Gastroenterologist practicing medicine in Atlanta, Georgia. Dr. Keilin is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Achalasia, Angiodysplasia of the Colon, Gastroparesis, Gastrectomy, and Endoscopy. Dr. Keilin is board certified in American Board Of Internal Medicine, 2007. Dr. Keilin is currently accepting new patients.

Frequently Asked Questions about Dr. Michael R. Galambos

How do I make an appointment with Dr. Michael R. Galambos?

You can book an appointment with Dr. Michael R. Galambos by calling their office at 404-355-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael R. Galambos a top-rated expert for Primary Biliary Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael R. Galambos is classified as an Distinguished expert for Primary Biliary Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael R. Galambos specialize in?

While Dr. Michael R. Galambos is a Gastroenterology, they have specific expertise in Primary Biliary Cholangitis, Turcot Syndrome, and Gardner Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Michael R. Galambos participate in research or clinical trials?

Yes. Dr. Michael R. Galambos has published 3 articles and abstracts on conditions like Primary Biliary Cholangitis. You can view a list of Dr. Michael R. Galambos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael R. Galambos accept my insurance?

Dr. Michael R. Galambos accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 404-355-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Galambos's expertise for a condition
ConditionClose
    View All 23 Distinguished Conditions
    View All 49 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile